Paris - Delayed Quote EUR

Biophytis S.A. (ALBPS.PA)

0.1320

-0.0050

(-3.65%)

At close: June 13 at 5:35:14 PM GMT+2

Biophytis Targets Mobility Restoration in Patients with Obesity

Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - April 22, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in developing treatments for age-related diseases strentghens its position as one of the leading players in preserving muscle function in patients with obesity treated with GLP-1 therapies. While these treatments are revolutionizing obesity care by delivering significant weight loss, they also induce a concer

Newsfile last month

BPTSY
Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity

Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - April 9, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, confirms the launch of the Phase 2 OBA clinical study in obesity, expected to begin as early as possible in 2025.Following the recent €2.6 million capital increase announced on March 26, 2025, and promising preclinical results presented at the 15th Int

Newsfile 2 months ago

BPTSY
Biophytis Announces New Non-Clinical Data Further Supporting Its Mission to Pioneer the Restoration of Mobility in Patients with Obesity

96% of patients with obesity report experiencing muscle strength impairment, affecting their mobilityNew preclinical study results: The combination of BIO101 and GLP-1 induced muscle strength and mobility restoration in animal modelParis, France and Cambridge, Massachusetts--(Newsfile Corp. - March 24, 2025) - Biophytis SA (FP: ALBPS) ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in developing treatments for age-related diseases, announces new preclinical re

Newsfile 2 months ago

BPTSY
Biophytis Revolutionizes Sarcopenia

Publication of SARA-INT Phase II results for BIO101Confirmation of Phase 3 readinessParis, France and Cambridge, Massachusetts--(Newsfile Corp. - March 17, 2025) - Biophytis SA (FP: ALBPS) ("Biophytis" or the "company"), a clinical-stage biotechnology company specialized in developing therapies for age-related diseases, is excited to announce a world premiere: the publication of the Phase 2 clinical trial SARA-INT in the Journal of Cachexia, Sarcopenia and Muscle (JCSM), the key reference journa

Newsfile 2 months ago

BPTSY
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum, held March 13th are now available for online viewing. REGISTER NOW AT: https://bit.ly/3DIWqav The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download

GlobeNewswire 2 months ago

PDSB

TELIF

BPTSY
Life Sciences Investor Forum Agenda Announced for March 13th

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum March 13th. This event is co-hosted by Zacks Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT: https://bit.ly/4hnure6 It is recommended that inve

GlobeNewswire 3 months ago

NGENF

BPTSY

HMTXF
Biophytis Announces its Participation in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR)

Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - February 25, 2025) - Biophytis SA (FP: ALBPS) ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, announces its participation in the International Conference on Frailty and Sarcopenia Research & Geroscience Task Force (ICFSR), taking place from March 12 to 14 ...

Newsfile 3 months ago

BPTSY
Biophytis Unveils Its Outlook Strategies for 2025

Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - February 11, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, today unveils its strategic outlook for the year 2025.Biophytis has improved its competitive positioning and fundamentals in recent months, paving the way for accelerated execution of its strategic roadmap: Launch of the OBA clinical development pr

Newsfile 3 months ago

BPTSY
Biophytis Announces Its Participation to the BIOMED FORUM Investor Conference

Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - January 27, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, announces its participation in the Biomed Forum organized by All Invest Securities on February 4, 2025, in Paris.The Biomed Forum is the annual event dedicated to the healthcare sector, fostering connections between biotech or medtech companies and

Newsfile 4 months ago

BPTSY
Biophytis and AskHelpU Sign a Co-Development Agreement in Rare Neuromuscular Diseases in China

Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - January 21, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, today announces the signing of a co-development agreement with AskHelpU, the largest patient association in China for those aﬀected by Amyotrophic lateral sclerosis (ALS).This co-development agreement aims to evaluate the eﬃcacy of BIO101, Biophytis

Newsfile 4 months ago

BPTSY
Biophytis Enters Exclusive Negotiations with a Chinese Pharmaceutical Company to License BIO101

Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - January 14, 2025) - Biophytis SA (OTC Pink: BPTSY) (FP: ALBPS) ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, announces that it has entered exclusive negotiations with a leading Chinese pharmaceutical company. The purpose of these discussions is to finalize a licensing agreement to co-develop and commercialize BIO101 (20-Hydroxyecdysone) in

Newsfile 4 months ago

BPTSY
Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS) ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on developing treatments for age-related diseases, publishes ...

ACCESS Newswire 8 months ago

BPTSY
Immunis to use MRI-based AI muscle analysis for sarcopenia trial

Immunis’ secretome therapy is being evaluated in elderly patients with knee osteoarthritis.

Medical Device Network 10 months ago

ALBPS.PA
-3.65%
Biophytis Deploys its Partnership Strategy and Signs Two Contracts with Local Agents in Asia

PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 22, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, ...

ACCESS Newswire 10 months ago

BPTSY
FDA approves Biophytis’ Phase II OBA obesity study

The multicentre study will assess the efficacy of BIO101 (20-hydroxyecdysone) in treating obesity.

Clinical Trials Arena 10 months ago

ALBPS.PA
-3.65%
Biophytis Obtains IND Approval from the FDA to Start its Phase 2 OBA Study in Obesity

PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 11, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, ...

ACCESS Newswire 10 months ago

BPTSY
Biophytis grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at up to €108 Million

Biophytis to receive upfront and milestones payments for a total amount up to €108 million, as well as double-digit royaltieson future sales of the product Agreement covers commercialization of BIO101 in Latin America Biophytis and Blanver intend ...

ACCESS Newswire 11 months ago

BPTSY

Performance Overview

Return	ALBPS.PA	CAC 40 (^FCHI)
YTD	-65.25%	+4.12%
1-Year	-79.69%	-0.30%
3-Year	-99.72%	+27.60%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Biophytis S.A. (ALBPS.PA)

Biophytis Targets Mobility Restoration in Patients with Obesity

Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity

Biophytis Announces New Non-Clinical Data Further Supporting Its Mission to Pioneer the Restoration of Mobility in Patients with Obesity

Biophytis Revolutionizes Sarcopenia

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

Life Sciences Investor Forum Agenda Announced for March 13th

Biophytis Announces its Participation in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR)

Biophytis Unveils Its Outlook Strategies for 2025

Biophytis Announces Its Participation to the BIOMED FORUM Investor Conference

Biophytis and AskHelpU Sign a Co-Development Agreement in Rare Neuromuscular Diseases in China

Biophytis Enters Exclusive Negotiations with a Chinese Pharmaceutical Company to License BIO101

Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities

Immunis to use MRI-based AI muscle analysis for sarcopenia trial

Biophytis Deploys its Partnership Strategy and Signs Two Contracts with Local Agents in Asia

FDA approves Biophytis’ Phase II OBA obesity study

Biophytis Obtains IND Approval from the FDA to Start its Phase 2 OBA Study in Obesity

Biophytis grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at up to €108 Million

Performance Overview